LLY

902.74

-0.9%↓

UNH

596.8

+0.31%↑

NVO

131.05

+0.18%↑

JNJ

164.37

-0.29%↓

MRK

117.82

-0.52%↓

LLY

902.74

-0.9%↓

UNH

596.8

+0.31%↑

NVO

131.05

+0.18%↑

JNJ

164.37

-0.29%↓

MRK

117.82

-0.52%↓

LLY

902.74

-0.9%↓

UNH

596.8

+0.31%↑

NVO

131.05

+0.18%↑

JNJ

164.37

-0.29%↓

MRK

117.82

-0.52%↓

LLY

902.74

-0.9%↓

UNH

596.8

+0.31%↑

NVO

131.05

+0.18%↑

JNJ

164.37

-0.29%↓

MRK

117.82

-0.52%↓

LLY

902.74

-0.9%↓

UNH

596.8

+0.31%↑

NVO

131.05

+0.18%↑

JNJ

164.37

-0.29%↓

MRK

117.82

-0.52%↓

Home・Listă Acțiuni・AbbVie Inc

AbbVie Inc

Închisă

Sector Sănătate

193.18 0.34

Cumpără Vinde

Rezumat

Modificarea prețului

24h

Curent

Minim

192.93

Maxim

194.14

Indicatori cheie
By Trading Economics
Venit	1M 1.4B
Vânzări	2.2B 14B
P/E Medie Sector	51.05 103.001
EPS	2.65
Marjă de profit	9.474
Angajați	50,000
EBITDA	514M 5B

Recomandări
By TipRanks
Recomandări	Cumpărare
Prognoză pe 12 luni	+2.24 upside

Dividende
By Dow Jones
Următoarele câștiguri	25 oct. 2024
Data viitoare de dividende	15 nov. 2024
Următoarea dată ex-dividende	15 oct. 2024

Statistici piață
By TradingEconomics
Capitalizare de piață	348B
Deschiderea anterioară	192.84
Închiderea anterioară	193.18

Sentimentul știrilor

By Acuity

24%

76%

39 / 365 Clasament în Healthcare

Scor tehnic

By Trading Central

Încredere

Very Strong Bearish Evidence

192.16 / 196.2271 Suport & Rezistență

AbbVie Inc Grafic

Știri relevante

25 iul. 2024, 12:18 UTC

Câștiguri

AbbVie 2Q Revenue Gets Boost From Skyrizi, Rinvoq Sales

27 iun. 2024, 13:58 UTC

Achiziții, Fuziuni, Preluări

AbbVie Buys Celsius Therapeutics for $250 Million

26 apr. 2024, 20:53 UTC

Principalele dinamici ale pieței

AbbVie Shares Close Down 4.6%, Sees Additional Humira Volume Erosion in 2Q

26 apr. 2024, 12:25 UTC

Câștiguri

AbbVie Lifts Outlook After 1Q Revenue Unexpectedly Rises

3 sept. 2024, 04:00 UTC

Top știri

Novo, Amgen, Other Pharma Stocks Have Clinical Trials That Could Send Them Soaring -- Barrons.com

12 aug. 2024, 14:30 UTC

Achiziții, Fuziuni, Preluări

Correction to Big Drugmakers Are Clinching Smaller Deals Article -- WSJ

12 aug. 2024, 09:30 UTC

Top știri

Achiziții, Fuziuni, Preluări

Big Drugmakers Are Clinching Smaller Deals -- WSJ

1 aug. 2024, 12:23 UTC

Achiziții, Fuziuni, Preluări

AbbVie Completes Acquisition Of Cerevel Therapeutics >ABBV CERE

29 iul. 2024, 10:30 UTC

Top știri

Big Pharma Rallies and Moves Past Obesity -- Heard on the Street -- WSJ

25 iul. 2024, 13:01 UTC

Câștiguri

AbbVie Slides Despite Beating Second-Quarter Views, Raising Guidance -- IBD

25 iul. 2024, 12:46 UTC

Top știri

Câștiguri

AbbVie Stock Is Rising on Strong Earnings. CEO Cites 'Significant Momentum.' -- Barrons.com

25 iul. 2024, 11:36 UTC

Câștiguri

AbbVie Sees FY Adj EPS $10.71-Adj EPS $10.91 >ABBV

25 iul. 2024, 11:36 UTC

Câștiguri

AbbVie 2Q Global Net Rev From Oncology Portfolio $1.63B >ABBV

25 iul. 2024, 11:36 UTC

Câștiguri

AbbVie 2Q EPS 77c >ABBV

25 iul. 2024, 11:36 UTC

Câștiguri

AbbVie 2Q Rev $14.46B >ABBV

25 iul. 2024, 11:36 UTC

Câștiguri

AbbVie 2Q Global Skyrizi Rev $2.73B >ABBV

25 iul. 2024, 11:36 UTC

Câștiguri

AbbVie 2Q U.S. HUMIRA Rev $2.36B >ABBV

25 iul. 2024, 11:36 UTC

Câștiguri

AbbVie 2Q International HUMIRA Rev $454M >ABBV

25 iul. 2024, 11:36 UTC

Câștiguri

AbbVie 2Q Adj EPS $2.65 >ABBV

25 iul. 2024, 11:36 UTC

Câștiguri

AbbVie 2Q Net $1.37B >ABBV

25 iul. 2024, 11:36 UTC

Câștiguri

AbbVie 2Q Global IMBRUVICA Rev $833M >ABBV

25 iul. 2024, 08:40 UTC

Top știri

These Stocks Are Moving the Most Today: Ford, Tesla, Alphabet, Nvidia, Super Micro, IBM, ServiceNow, Chipotle, and More -- Barrons.com

27 iun. 2024, 13:28 UTC

Achiziții, Fuziuni, Preluări

AbbVie Acquires Celsius for $250 Million in Cash >ABBV

27 iun. 2024, 13:28 UTC

Achiziții, Fuziuni, Preluări

AbbVie: Celsius' Lead Asset Has Completed Phase 1 Study in Inflammatory Bowel Disease >ABBV

27 iun. 2024, 13:26 UTC

Achiziții, Fuziuni, Preluări

AbbVie Acquires Celsius Therapeutics >ABBV

23 mai 2024, 20:05 UTC

Achiziții, Fuziuni, Preluări

AbbVie Completes Acquisition Of Landos Biopharma >ABBV LABP

7 mai 2024, 20:30 UTC

Top știri

Teva Earnings Are Soon. What Could Keep the Stock Gains Going. -- Barrons.com

26 apr. 2024, 13:03 UTC

Câștiguri

AbbVie Beats First-Quarter Views As Skyrizi Looks To Take Humira's Title -- IBD

26 apr. 2024, 12:04 UTC

Câștiguri

AbbVie Raises Earnings Guidance Even as Humira Sales Continue to Drop -- Barrons.com

26 apr. 2024, 11:41 UTC

Câștiguri

AbbVie 1Q Adjusted EPS Cut 8c by Acquired IPR&D, Milestones Expense >ABBV

Comparație

Modificare preț

AbbVie Inc Așteptări

Obiectiv de preț

By TipRanks

2.24% sus

Prognoză pe 12 luni

Medie 197.73 USD 2.24%

Maxim 218 USD

Minim 170 USD

În baza a 15 analiști de pe Wall Street care oferă obiective de preț pe 12 luni pentruAbbVie Inc - Dist în ultimele 3 luni.

Consens privind evaluarea

By TipRanks

Cumpărare

15 ratings

Cumpărare

Păstrare

Vânzare

Ținând cont de 15 analiști care au acordat evaluări ale acțiunilor AbbVie Inc - Dist în ultimele 3 luni.

Scor tehnic

By Trading Central

192.16 / 196.2271Suport & Rezistență

Recent bearish events outweigh bullish events.

Bullish events outweigh bearish events.

There is one bullish event.

Sentiment

By Acuity

39 / 365 Clasament în Sănătate

Date financiare

Cheltuieli de vânzare și administrare

Cheltuieli de exploatare

Profit pre-impozitare

Vânzări

Costul vânzărilor

Profit brut din vânzări

Cheltuieli cu dobânzile pe datorie

EBITDA

Profit operațional

Despre AbbVie Inc

AbbVie Inc. (AbbVie) is a research-based biopharmaceutical company. The Company is engaged in research and development, manufacturing, commercialization and sale of medicines and therapies. AbbVie offers its products in various therapeutic categories, including Immunology products, which include Humira, Skyrizi and Rinvoq; Oncology products consists of Imbruvica and Venclexta; Aesthetics products include Botox Cosmetic, Juvederm Collection and other aesthetics; Neuroscience products, such as Botox Therapeutic, Vraylar, Duopa and Duodopa, and Ubrelvy; Eye care products consists of Lumigan, Alphagan and Restasis ; Women's health products incudes Lo Loestrin, Orilissa and other women's health; and Other key products, which includes Mavyret, Creon, Lupron, Linzess and Synthroid. The Company's products are sold worldwide directly to wholesalers, distributors, government agencies, health care facilities and independent retailers from AbbVie-owned distribution centers and public warehouses.